The risk of developing AML is very high: more than 80%. AML associated with familial CEBPA deficiency appears to have an earlier onset than sporadic, non-familial AML. While the average age of diagnosis for the former is 25 years, it greatly varies: from not quite 2 to > 45 years of age. In comparison, the average age when sporadic AML is diagnosed is 65 years of age.
The prognosis for the familial form of AML appears to be better than that for sporadic AML. 67% of patients are still alive after 10 years.
Even after AML has been overcome, patients with familial CEBPA deficiency are still at risk of developing leukemia again.